Asher Chanan-khan - Net Worth and Insider Trading

Asher Chanan-khan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Asher Chanan-khan owns 1 companies in total, including Cellectar Biosciences Inc (CLRB) .

Click here to see the complete history of Asher Chanan-khan’s form 4 insider trades.

Insider Ownership Summary of Asher Chanan-khan

Ticker Comapny Transaction Date Type of Owner
CLRB Cellectar Biosciences Inc 2021-06-23 director

Asher Chanan-khan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Asher Chanan-khan Ownership Network

Ownership Network List of Asher Chanan-khan

No Data

Ownership Network Relation of Asher Chanan-khan

Insider Network Chart

Asher Chanan-khan Owned Company Details

What does Cellectar Biosciences Inc do?

Who are the key executives at Cellectar Biosciences Inc?

Asher Chanan-khan is the director of Cellectar Biosciences Inc. Other key executives at Cellectar Biosciences Inc include Senior Vice President & Medical Andrei Shustov , Chief Commercial Officer Darrell Shane Lea , and Chief Financial Officer Chad J Kolean .

Cellectar Biosciences Inc (CLRB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cellectar Biosciences Inc (CLRB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cellectar Biosciences Inc (CLRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cellectar Biosciences Inc (CLRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cellectar Biosciences Inc Insider Transactions

No Available Data

Asher Chanan-khan Mailing Address

Above is the net worth, insider trading, and ownership report for Asher Chanan-khan. You might contact Asher Chanan-khan via mailing address: C/o Cellectar Bisciences, Inc., 100 Campus Drive Nj 07932.

Discussions on Asher Chanan-khan

No discussions yet.